SL
SLN.US Silence Therapeutics PLC
- Market cap
- USD 1.23B
- P/E
- -
- P/B
- 5.73x
- ROE
- -24.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SLN.US undervalued?
Graham numberThe Graham number of Silence Therapeutics PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Silence Therapeutics PLC fundamental analysis
No fundamental analysis for Silence Therapeutics PLC yet.
Silence Therapeutics PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Silence Therapeutics PLC
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease…
Full company profileSilence Therapeutics PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Silence Therapeutics PLC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 770K | 16.0K | 0.00 | 244K | 5.48M | 12.4M | 17.7M | 25.4M | 43.3M | 559K | 562K |
| Gross Profit | -7.94M | -7.93M | -9.74M | 244K | 1.72M | 4.96M | 6.68M | 15.1M | 31.4M | 344K | 120K |
| Operating Income | -11.9M | -14.4M | -20.6M | -22.7M | -35.8M | -45.8M | -49.8M | -49.6M | -63.3M | -89.8M | -56.5M |
| EBITDA | -11.6M | -3.33M | -20.2M | -22.4M | -35.5M | -45.4M | -39.9M | -49.8M | -49.1M | -88.0M | -53.5M |
| Net Income | -8.44M | -1.62M | -18.4M | -19.6M | -32.5M | -39.4M | -41.0M | -43.3M | -45.3M | -88.6M | -52.9M |
| EPS | -0.36 | -0.07 | -0.79 | -0.78 | -1.19 | -1.33 | -3.82 | -3.50 | -2.94 | -5.63 | -0.96 |
| Balance Sheet | |||||||||||
| Total Assets | 55.8M | 55.0M | 38.9M | 46.1M | 86.0M | 96.2M | 108M | 94.5M | 162M | 131M | 281M |
| Total Liabilities | 1.61M | 2.66M | 3.83M | 25.2M | 76.9M | 87.7M | 85.4M | 77.1M | 54.8M | 69.1M | 66.5M |
| Shareholders' Equity | 54.2M | 52.4M | 35.1M | 20.9M | 9.06M | 8.53M | 22.1M | 22.0M | 107M | 62.3M | 215M |
| Cash & Short-term Investments | 39.0M | 43.1M | 26.5M | 33.5M | 37.4M | 73.5M | 71.1M | 54.4M | 118M | 85.1M | 248M |
| Total Debt | - | - | - | 287K | 341K | 137K | 446K | 274K | 93.5K | 160K | -87.0K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -10.1M | -9.60M | -16.8M | 1.73M | -10.8M | 9.19M | -57.0M | -39.4M | -54.1M | -62.3M | -35.8M |
| Capital Expenditure | 537K | 173K | 188K | 9.00K | 514K | 1.80M | 545K | 45.0K | 169K | 55.0K | 8.00 |
| Free Cash Flow | -10.6M | -9.77M | -16.9M | 1.72M | -11.3M | 7.39M | -57.6M | -39.4M | -54.2M | -62.3M | -35.8M |
| Ratios | |||||||||||
| ROE | -15.6% | -3.1% | -52.5% | -93.7% | -359.3% | -462.2% | -185.9% | -196.7% | -42.3% | -142.2% | -24.6% |
| ROA | -15.1% | -2.9% | -47.3% | -42.5% | -37.9% | -41.0% | -38.2% | -45.8% | -28.0% | -67.4% | -18.8% |
| Net Profit Margin | -1,096.1% | -10,112.5% | - | -8,025.4% | -594.0% | -317.4% | -232.4% | -170.5% | -104.7% | -15,851.9% | -9,411.1% |
| Debt to Equity | - | - | - | 0.01x | 0.04x | 0.02x | 0.02x | 0.01x | 0.00x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Silence Therapeutics PLC dividends
Silence Therapeutics PLC has not paid dividends in the last 9 fiscal years.
Who owns Silence Therapeutics PLC
- Insiders 7.71%
- Institutions 80.98%
- Public & others 11.30%
- Shares outstanding 62.2M
- Free float 53.3M
Top funds holding SLN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Select Biotechnology | 2.04M | 1.09% | +1,865.99% | Aug 2026 |
| Fidelity Small Cap Growth | 915K | 0.49% | 0.00% | Aug 2026 |
| MEDICAL BioHealth EUR Acc | 837K | 0.45% | +54.04% | Aug 2026 |
| Fidelity Advisor Biotechnology I | 532K | 0.29% | 0.00% | Sep 2026 |
| Fidelity Select Health Care | 500K | 0.27% | 0.00% | Aug 2026 |
| Fidelity Small Cap Growth K6 | 479K | 0.26% | 0.00% | Aug 2026 |
| International Biotechnology Ord | 466K | 0.25% | -22.86% | Jul 2026 |
| apo Medical Opportunities R | 391K | 0.21% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 290K | 0.16% | -0.19% | Oct 2026 |
| Strategic Advisers Fidelity US TtlStk | 232K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Advisor Health Care I | 228K | 0.12% | 0.00% | Sep 2026 |
| abrdn World Healthcare | 206K | 0.11% | +96.06% | Sep 2026 |
| RIM Global Bioscience EUR | 116K | 0.06% | 0.00% | Jul 2026 |
| Alger Small Cap Growth A | 111K | 0.06% | +5.39% | Aug 2026 |
| Alger Small Cap Growth I-2 | 92.9K | 0.05% | +11.33% | Aug 2026 |
| Fidelity VIP Health Care Initial | 85.0K | 0.05% | 0.00% | Sep 2026 |
| Strategic Advisers U.S. Total Stock | 85.0K | 0.05% | 0.00% | Sep 2026 |
| Galileo - Biotech Innovation Fund S USD | 58.6K | 0.03% | 0.00% | Apr 2026 |
| Alger Small Cap Growth Institutional I | 48.0K | 0.03% | +16.13% | Aug 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 41.9K | 0.02% | +0.20% | Oct 2026 |
Top institutions holding SLN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Siren, L.L.C. | 3.31M | 1.77% | +13.74% | Jun 2026 |
| TCG Crossover Management, LLC | 3.03M | 1.63% | 0.00% | Jun 2026 |
| Nantahala Capital Management, LLC | 2.69M | 1.44% | +25.47% | Jun 2026 |
| Redmile Group, LLC | 2.16M | 1.16% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 1.33M | 0.71% | +7.68% | Jun 2026 |
| Nextech Invest, Ltd. | 952K | 0.51% | 0.00% | Jun 2026 |
| Millennium Management LLC | 909K | 0.49% | -15.35% | Jun 2026 |
| Ikarian Capital, LLC | 831K | 0.45% | -4.04% | Jun 2026 |
| Polygon Management Ltd | 764K | 0.41% | +21.28% | Jun 2026 |
| Soleus Capital Management, L.P. | 630K | 0.34% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 611K | 0.33% | 0.00% | Jun 2026 |
| 5AM Venture Management, LLC | 476K | 0.26% | 0.00% | Jun 2026 |
| Great Point Partners LLC | 450K | 0.24% | -55.90% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 403K | 0.22% | +515.66% | Jun 2026 |
| Ameriprise Financial Inc | 370K | 0.20% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 369K | 0.20% | +265.76% | Jun 2026 |
| ADAR1 Capital Management LLC | 338K | 0.18% | +96.55% | Jun 2026 |
| SummitTX Capital, L.P | 327K | 0.18% | 0.00% | Jun 2026 |
| Schonfeld Strategic Advisors LLC | 269K | 0.14% | 0.00% | Jun 2026 |
| UBS Group AG | 243K | 0.13% | -1.53% | Jun 2026 |
Silence Therapeutics PLC company profile
- Company name
- Silence Therapeutics PLC
- Ticker
- SLN.US
- Exchange
- USA Stocks
- Listed since
- Sep 8, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 88
- Fiscal year end
- December
- Address
- 12 Hammersmith Grove, London, United Kingdom, W6 7AP
- Phone
- 44 20 3457 6900
- Website
- silence-therapeutics.com
About Silence Therapeutics PLC
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
Silence Therapeutics PLC management
9- Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.DInterim CEO & Chairman of the Board · born 1954
- Ms. Rhonda L. HellumsExecutive VP, CFO, Secretary & Executive Director · born 1971
- Dr. Steven J. Romano M.D.Executive VP and Chief Research & Development Officer · born 1959
- Dr. Marie Wikstrom Lindholm Ph.D.Chief Scientific Officer
- Ms. Gem Gokmen HopkinsVP and Head of IR & Corporate Communications
- Mr. Jaimin B. ShahSVP & General Counsel
- Mr. J.P. GabrielChief Technical Operations Officer
- Mr. Curtis Rambaran M.D.Chief Medical Officer
- Ms. Marianna AnestiVP & Head of Business Development